Stockscreener 앱 받기
55.99
0.78%
-0.44
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Retail Surge: What is the dividend yield of Crinetics Pharmaceuticals Inc2025 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Crinetics Pharmaceuticals exec sells shares worth $195,350 - MSN
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral - Insider Monkey
Hedge Fund Bets: Can Crinetics Pharmaceuticals Inc be recession proofEarnings Risk Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Why Crinetics Pharmaceuticals (CRNX) Is Up 18.2% After Equity Raise and PALSONIFY, Atumelnant Updates - Sahm
Crinetics Pharmaceuticals discovers new SSTR2 non-peptide-drug conjugates - BioWorld MedTech
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Goldman Sachs Upgrades Crinetics Pharmaceuticals (CRNX) - Nasdaq
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CRNX Upgraded to 'Buy' by Goldman Sachs with New Price Target of $67 | CRNX Stock News - GuruFocus
Crinetics Shares Rise After Goldman Sachs Upgrade - marketscreener.com
The Goldman Sachs Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy - MarketBeat
Crinetics stock rating upgraded by Goldman Sachs on promising CAH drug data - Investing.com Canada
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
How Crinetics Pharmaceuticals Inc. stock trades during market volatility2025 Earnings Surprises & Weekly High Return Stock Opportunities - Улправда
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Crinetics Pharmaceuticals prices offering at $45.95 per share - MSN
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Strong Share Price Momentum - Sahm
What risks investors should watch in Crinetics Pharmaceuticals Inc. stockLong Setup & Safe Capital Investment Plans - Улправда
Is Crinetics Pharmaceuticals Inc. stock overvalued by current metricsWeekly Trend Report & High Conviction Trade Alerts - Улправда
Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersTrade Volume Summary & Technical Pattern Alert System - ulpravda.ru
Gains Report: Does Crinetics Pharmaceuticals Inc. stock trade at a discount to peersJuly 2025 Spike Watch & Safe Capital Preservation Plans - ulpravda.ru
Analyst Calls: How risky is Crinetics Pharmaceuticals Inc. stock nowJuly 2025 Outlook & Risk Controlled Stock Pick Alerts - Улправда
Citizens Jmp Has Lowered Expectations for Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price - MarketBeat
Crinetics Pharmaceuticals (CRNX): Analyst Updates on Price Targe - GuruFocus
Crinetics stock price target lowered to $105 by Citizens on endocrinologist survey - Investing.com UK
Crinetics Pharmaceuticals prices public offering at $45.95 per share By Investing.com - Investing.com Nigeria
US Market Wrap: Will Crinetics Pharmaceuticals Inc 6Z4 stock issue positive guidance2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Crinetics (CRNX) Sees Significant Stock Price Increase - GuruFocus
Crinetics Pharma CCO Kalofonos sells $137,500 in shares By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals’ Positive Trial Results and Stock Target Uplift Spark Optimism - StocksToTrade
Crinetics Announces Major Public Offering to Fund Growth - TipRanks
Crinetics’ Stocks Surge: Promising Future or Mirage? - timothysykes.com
Crinetics Pharmaceuticals Announces Public Offering of Common Stock - TradingView — Track All Markets
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Crinetics Shares Rise After Pricing $350 Million Stock Offering - marketscreener.com
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial - Asianet Newsable
Crinetics Pharmaceuticals’ Stock Surges after Positive Trial Results and Analyst Boosts - timothysykes.com
Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits - TechStock²
Crinetics (CRNX) Stock Soars Over 12% Amid Market Activity - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up Following Analyst Upgrade - MarketBeat
Why Crinetics Pharmaceuticals Shares Are Sinking Today - TipRanks
Crinetics Pharma climbs after $350 mln stock sale - TradingView — Track All Markets
Crinetics Pharmaceuticals (CRNX) Stock Analysis: A Deep Dive Into 71% Upside Potential - DirectorsTalk Interviews
Crinetics Prices $350 Million Stock Offering - marketscreener.com
Crinetics Pharmaceuticals prices public offering at $45.95 per share - Investing.com
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock - The Manila Times
Crinetics Pharmaceuticals Prices Public Offering of 7.62 Million Shares at $45.95 Each, Anticipating $350 Million in Proceeds - Quiver Quantitative
Biotech plans $350M raise to launch PALSONIFY and fund R&D - Stock Titan
Crinetics Pharmaceuticals prices public offering of 7.6 million shares at $45.95 each - marketscreener.com
Crinetics Prices 7.62M Share Offering at $45.95, Raising $350M - Intellectia AI
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 8.2%Here's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Exact Sciences (EXAS) - The Globe and Mail
CRNX Stock: Morgan Stanley Raises Price Target to $80 | CRNX Sto - GuruFocus
4.73%
0.92%
자본화:
|
볼륨(24시간):